mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-30. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
The erlang, named after A. K. Erlang, as a dimensionless unit is used in telephony as a statistical measure of the offered intensity of telecommunications traffic on a group of resources. Traffic of one erlang refers to a single resource being in continuous use, or two channels being at fifty percent use, and so on, pro rata. Much telecommunications management and forecasting software uses this.
Antithrombotic medication. These are commonly given because thromboembolism is the major cause of arterial embolism. Examples are: Anticoagulants (such as warfarin or heparin) and antiplatelet medication (such as aspirin, ticlopidine, and clopidogrel) can prevent new clots from forming Thrombolytics (such as streptokinase) can dissolve clots Painkillers given intravenously Vasodilators to relax and dilate blood vessels. Appropriate drug treatments successfully produce thrombolysis and removal of the clot in 50% to 80% of all cases. Antithrombotic agents may be administered directly onto the clot in the vessel using a flexible catheter (intra-arterial thrombolysis). Intra-arterial thrombolysis reduces thromboembolic occlusion by 95% in 50% of cases, and restores adequate blood flow in 50% to 80% of cases. Surgical procedures include:
Furthermore, NASA gathered and published data indicating a significant heat signature at the military base, suggesting that a sizeable fire had erupted at the site overnight. In Kandahar, Pakistani officials released aerial footage of a large explosion at an ammunition depot near Kandahar International Airport (KDH). BBC News, using satellite imagery, confirmed the location of an ammunition depot in Kandahar. In Paktika, a video shared on social media showed smoke rising from a Taliban military base in the Urgun District. BBC News confirmed the location by matching roads and a distinctive foreground building with satellite imagery. Analysts at Maiar, an intelligence firm, stated that Pakistan's strikes on buildings and other infrastructure in Afghanistan appeared to be largely confined to military sites. They said that one of the buildings struck in Kabul appeared to be a military headquarters or command-and-control centre, and that vehicles parked nearby suggested the building had been occupied. In Kandahar, the analysts reported damage to at least two buildings within a large complex, which they assessed to be a headquarters of some kind. PAF airstrikes in Kandahar province also struck the former home of Mullah Omar, the late founder of the Taliban, which was currently serving as a base for the Taliban's suicide unit. The property is located about one kilometer from the residence of the current Taliban leader, Hibatullah Akhundzada. According to local Afghan sources, about 15 Taliban members were killed in the strike.
An X-ray of swallowed barium may be used to reveal the size and shape of the esophagus, and the presence of any masses. The esophagus may also be imaged using a flexible camera inserted into the esophagus, in a procedure called an endoscopy. If an endoscopy is used on the stomach, the camera will also have to pass through the esophagus. During an endoscopy, a biopsy may be taken. If cancer of the esophagus is being investigated, other methods, including a CT scan, may also be used.
Sources: en.wikipedia.org
The existence of anthropomorphic images and half-human, half-animal images in the Upper Paleolithic may further indicate that Upper Paleolithic humans were the first people to believe in a pantheon of gods or supernatural beings, though such images may instead indicate shamanistic practices similar to those of contemporary tribal societies. The earliest known undisputed burial of a shaman (and by extension the earliest undisputed evidence of shamans and shamanic practices) dates back to the early Upper Paleolithic era (c. 30,000 BP) in what is now the Czech Republic. However, during the early Upper Paleolithic it was probably more common for all members of the band to participate equally and fully in religious ceremonies, in contrast to the religious traditions of later periods when religious authorities and part-time ritual specialists such as shamans, priests and medicine men were relatively common and integral to religious life. Religion was possibly apotropaic; specifically, it may have involved sympathetic magic. The Venus figurines, which are abundant in the Upper Paleolithic archaeological record, provide an example of possible Paleolithic sympathetic magic, as they may have been used for ensuring success in hunting and to bring about fertility of the land and women. The Upper Paleolithic Venus figurines have sometimes been explained as depictions of an earth goddess similar to Gaia, or as representations of a goddess who is the ruler or mother of the animals.
Existential risk researchers analyze risks that could lead to human extinction or civilizational collapse, and look for ways to build resilience against them. Relevant research centers include the Cambridge Center for the Study of Existential Risk and the Stanford Existential Risk Initiative. Future technologies may contribute to the risks of artificial general intelligence, biological warfare, nuclear warfare, nanotechnology, anthropogenic climate change, global warming, or stable global totalitarianism, though technologies may also help to mitigate asteroid impacts and gamma-ray bursts. In 2019, philosopher Nick Bostrom introduced the notion of a vulnerable world, "one in which there is some level of technological development at which civilization almost certainly gets devastated by default", citing the risks of a pandemic caused by bioterrorists, or an arms race triggered by the development of novel armaments and the loss of mutual assured destruction. He invites policymakers to question the assumptions that technological progress is always beneficial, that scientific openness is always preferable, or that they can afford to wait until a dangerous technology has been invented before they prepare mitigations.
Before the establishment of the State of Israel in 1948, the Druze lived in the Galilee and Mount Carmel, either in exclusively Druze villages or in villages mixed with Christians, where they had coexisted for centuries. Historically, the relationship between the Druze and their Christian neighbors was better compared to their relationship with their Muslim neighbors in neighboring villages. According to historian Ilan Pappé, during the 1948 Arab–Israeli War, in villages partly inhabited by Druze, Christians were generally exempt from expulsion. According to Pappé, in 1948, Israeli military rulers gathered Christians in the centers of several villages in the Galilee region, planning to deport them. However, Druze village leaders intervened, insisting that all Christians remain in their homes. They utilized all their influence and resources to ensure that the Christian residents could stay. The Galilean village of Rameh, with a Christian majority, was not displaced because of its large Druze population. While the "divide and rule" policy succeeded with the Druze, who were promised immunity, weapons, and privileges, by the Zionist militias, the Palestinian Christian communities were less "cooperative". Israeli Druze and Muslims have comparable socio-economic standards when compared to their wealthier and more educated Israeli Christian counterparts.
== Diagnosis == Buried bumper syndrome may be suspected based on features consistent with this disorder. The diagnosis is confirmed either endoscopically (via upper endoscopy) or with computed tomography. Upper endoscopy may reveal overgrowth of stomach tissue over the internal bumper (incomplete buried bumper syndrome). If the bumper has eroded deep into the gastric mucosa, it may not be visualized during endoscopic evaluation (complete buried bumper syndrome).
The chloroplastida group is another large, highly diverse lineage that includes both green algae and land plants. This group is also called Viridiplantae, which includes two core clades—Chlorophyta and Streptophyta. Most green chloroplasts are green in color, though some aren't due to accessory pigments that override the green from chlorophylls, such as in the resting cells of Haematococcus pluvialis. Green chloroplasts differ from glaucophyte and red algal chloroplasts in that they have lost their phycobilisomes, and contain chlorophyll b. They have also lost the peptidoglycan wall between their double membrane, leaving an intermembrane space. Some plants have kept some genes required for the synthesis of peptidoglycan, but have repurposed them for use in chloroplast division instead. Chloroplastida lineages also keep their starch inside their chloroplasts. In plants and some algae, the chloroplast thylakoids are arranged in grana stacks. Some green algal chloroplasts, as well as those of hornworts, contain a structure called a pyrenoid, that concentrate RuBisCO and CO2 in the chloroplast, functionally similar to the glaucophyte carboxysome. There are some lineages of non-photosynthetic parasitic green algae that have lost their chloroplasts entirely, such as Prototheca, or have no chloroplast while retaining the separate chloroplast genome, as in Helicosporidium. Morphological and physiological similarities, as well as phylogenetics, confirm that these are lineages that ancestrally had chloroplasts but have since lost them.
Sources: en.wikipedia.org
== Protein A antibody binding == It has been shown via crystallographic refinement that the primary binding site for protein A is on the Fc region, between the CH2 and CH3 domains. In addition, protein A has been shown to bind human IgG molecules containing IgG F(ab')2 fragments from the human VH3 gene family. Protein A can bind with strong affinity to the Fc portion of immunoglobulin of certain species as shown in the below table.
=== Disadvantages === The most substantial disadvantage of the MSi-TDP approach is the inherent 'MW barrier' that limits routine proteoform analysis to species less than ~20-30 kDa; indeed, there is a sharp decrease in the signal/noise ratio beyond the 20-30 kDa mass range, mainly due to the increase in the number of charge states the individual proteoform molecules can have as sequence length increases. While a handful of larger proteoforms have been successfully identified and are routinely measured in biopharma QC (although high concentrations are injected), successful fragmentation for comprehensive sequence coverage remains difficult as only a single charge state is selected for fragmentation, meaning a diluted signal yields fewer fragments. Realistically, although clearly powerful (and influential), MSi-TDP thus assesses only a minor MW-sub-proteome but cannot currently deliver routine, truly comprehensive total proteome analyses as identified species >30kDa are vanishingly few relative to even the estimated size of native proteomes. Efforts to manage the MW limitation have used the somewhat inappropriately named 'middle-down' approach, utilizing select proteases to digest larger proteoforms into manageable fragments; in effect, this is a variation of iTDP if the intact proteoform was first isolated (e.g. by gel or LC). Thus, the lack of intact proteoform fractionation methods, that are integrated with tandem MS, continues to plague substantive advances in MSi-TDP over the last 2-3 decades.
== Features == SENP1 (Sentrin-specific protease 1) is a human protease of 643 amino acids with a molecular weight of 73 kDa, EC number in humans 3.4.22.B70. It adopts a conformation that identifies it as a member of the superfamily of cysteine proteases, which contain a catalytic triad with three characterized amino acids: a cysteine at position 603, a histidine at position 533 and aspartic acid at position 550. The primary nucleophile is cysteine located at the N-terminal alpha helix of the protein core. The other two amino acids, aspartate and histidine, are located in the end of a beta sheet.
==== False information and fines ==== During the elections, Jornal da Band released false polling that showed Melo in the lead against d'Ávila. Melo's campaign would later post their findings onto his Instagram account. Jornal da Band would later correct the polling data and Melo's campaign removed the post from social media. He was later condemned by electoral courts under the Brazilian Election Justice and was made to pay 106,000 reais for spreading false information. The judge that made the decision made the call to forward the case to the Federal Police for a criminal investigation. Melo and Gomes were fined again through the Election Justice for 41,900 reais for a series of irregularities in the campaign's finances, including the use of provisions to print religiously styled pamphlets that displayed him appearing alongside city council candidates from the PTB, a party that had not formally become a member of his coalition. Allies of Melo also went around the city to spread rumors that if d'Ávila was elected, that she would close the city's churches and force people to eat dog meat.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.